Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOVE: Teriparatide vs Risedronate in Patients with Hip Fracture
NCT00887354Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2009
- Primary completion
- Aug 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 12
01
Overview
Phase 4, randomised, double-blind trial of teriparatide in osteoporosis, sponsored by Eli Lilly and Company. Primary endpoint: Change in Lumbar Spine Areal Bone Mineral Density at 78 weeks. Started Apr 2009; status: completed.
02
Drugs
teriparatide
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT00887354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00887354.